Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 226

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 226
---
 of Company Shares eligible for resale in the public market. The dilution, as a percentage of outstanding Company Shares, caused by the exercise of the APx Warrants will increase if a large number of our shareholders elect to redeem their Public Shares in connection with the Business Combination. Further, the redemption of Public Shares without any accompanying redemption of Public Warrants will increase the dilutive effect of the exercise of APx Warrants. Sales of substantial numbers of such Company Shares in the public market or the fact that such APx Warrants may be exercised could adversely affect the market price of Company Shares. However, there is no guarantee that the APx Warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. 92 Even if the Business Combination is consummated, APx Warrants may never be in the money, and they may expire worthless and the terms of the APx Warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then -outstanding APx Warrants approve of such amendment. APx Warrants were issued in registered form under the SPAC Warrant Agreement. The SPAC Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder for the purpose of curing any ambiguity, including to confirm the provisions of the SPAC Warrant Agreement to the description of the terms of the APx Warrants and the SPAC Warrant Agreement set forth in APx’s IPO prospectus, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under the SPAC Warrant Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the holders. The SPAC Warrant Agreement, however, requires the approval by the holders of at least a majority of the then -outstandingAPx Warrants to make any change that adversely affects the interests of the registered holders of APx Warrants. Accordingly, we may amend the terms of the APx Warrants in a manner adverse to a holder if holders of at least a majority of the then -outstandingAPx Warrants approve of such amendment. Although our ability to amend the terms of the APx Warrants with the consent of at least a majority of the then -outstandingAPx Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the APx